Alveofact 50mg Injection: Effective Medication for Professional Use

Alveofact 50mg Injection

Description:

• Contains an active component called Phospholipid fraction from bovine lung.
• Primarily used in the treatment of respiratory distress syndrome (RDS) in premature infants.
• May also be used in severe cases of pneumonia and meconium aspiration syndrome.

Uses:

• Neonatal respiratory distress syndrome (RDS).
• Meconium aspiration syndrome.
• Pneumonia.
• Acute respiratory distress syndrome (ARDS).
• Lung surfactant deficiency.

Therapeutic Effects:

• Reduces surface tension at the air-liquid interface in the lungs' alveoli, preventing collapse during exhalation.
• Enhances lung compliance, making breathing easier.
• Improves lung function and prevents breathing complications in conditions like RDS or surfactant deficiencies.

Contraindications:

• Individuals with known severe allergies to components of the Alveofact 50mg Injection or any of its components should not receive it.
• Active or severe infections may be a contraindication due to the potential risk of worsening the infection.
• Not recommended for infants above a certain gestational age or weight threshold.
• Consult a healthcare provider before taking it if the patient has a severe bleeding disorder or an increased risk of bleeding.

Interaction with other drugs:

• Inform the doctor about all medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products.
• Certain medications may interact with the Alveofact 50mg Injection, reducing effectiveness or causing undesirable side effects.

Storage:

• Stored at controlled room temperature, between 2°C to 8°C.
• Keep away from moisture, heat, and light.
• Should not be frozen.
• Keep away from children and pets.

Administration:

• Should be used only when there is enough facility for ventilation and monitoring.
• Administered via the intra-tracheal route.
• Constant monitoring by the baby’s physician and nurse is required to ensure that the right amount of oxygen is given.

Safety Advices:

• Pregnancy: Alveofact 50mg Injection is not directly associated with pregnancy or breastfeeding concerns, as it is primarily used in neonates and infants. However, pregnant individuals should consult healthcare providers before handling or administering surfactant medications.
• Breastfeeding: Breastfeeding individuals should consult healthcare providers before handling or administering Alveofact 50mg Injection.
• Lungs: Consult your healthcare provider before taking Alveofact 50mg Injection if you have lung diseases.
• Liver: There's limited information available regarding the impact of Alveofact 50mg Injection. It is recommended to consult your healthcare provider for personalized advice.
• Alcohol: There's no direct contraindication regarding alcohol consumption and Alveofact 50mg Injection. Consult your healthcare provider for better advice.
• Driving: Alveofact 50mg Injection does not typically directly affect driving ability. If you experience any side effects, consult your healthcare provider.

Side Effects:

• Serious: Airway blockage, infection, allergic reactions, pulmonary hemorrhage.
• Common: Transient oxygen desaturation, changes in heart rate, breathing difficulties.

Word of Advice:

• Ensure Alveofact 50mg Injection administration is conducted by trained healthcare professionals familiar with the procedure to minimize the risk of complications.
• Have proper ventilatory support available before and during administration to manage potential changes in oxygen levels or breathing difficulties.
• Continuously monitor vital signs, oxygen levels, and respiratory status during and after administration.
• Adhere strictly to aseptic techniques during administration to minimize the risk of infection.
• Ensure proper patient positioning to facilitate the administration process and minimize the risk of aspiration or airway obstruction.
• Conduct a thorough risk assessment, especially in cases of underlying lung conditions or compromised respiratory function.

FAQs:

1. What are the common side effects of Alveofact 50mg Injection? Common side effects may include transient oxygen desaturation, changes in heart rate, and temporary breathing difficulties. Serious but rare side effects might include airway blockage, infections, allergic reactions, or pulmonary hemorrhage.

2. Who administers Alveofact 50mg Injection? Alveofact 50mg Injection is administered by trained healthcare professionals, such as neonatologists, pediatricians, or pulmonologists.

3. Is Alveofact 50mg Injection always successful in improving lung function? While Alveofact 50mg Injection often improves lung function, individual responses can vary. In some cases, additional support or alternative treatments might be needed.

4. Can Alveofact 50mg Injection be repeated if needed? Yes, additional doses or repeated administration might be necessary, especially in ongoing respiratory distress or surfactant deficiencies.

5. Does Alveofact 50mg Injection impact long-term lung health? Evidence suggests that Alveofact 50mg Injection in neonates with RDS can improve short-term outcomes, potentially influencing long-term lung health. Further research is ongoing to understand its precise long-term effects.

6. How can one know if Alveofact 50mg Injection is effective? The effectiveness is assessed based on improved respiratory function, reduced breathing difficulties, and better oxygenation levels observed post-administration. Healthcare providers monitor these parameters closely.

Fact Box:

• Molecule name: Alveofact 50mg Injection.
• Therapeutic class: Pulmonary surfactants.
• Pharmacological class: Exogenous pulmonary surfactant.

टैग्स: medical-drug, injection, alveofact, pharmaceutical, 50mg